


FORM PTO-1449 (Modified)		Attorney Docket No.: 195531-001810US		Application No.: 09/808442		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Hugh Y. Rienhoff, Jr. et al.		Filing Date: March 13, 2001		
				Group: Not Yet Assigned		
Reference Designation		U.S. PATENT DOCUMENTS			Page 1	
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<u>AA</u>	5,966,712	10/12/99	Sabatini et al.	707	104	
<u>AB</u>	5,970,500	10/19/99	Sabatini et al.	707	104	
<u>AC</u>	5,972,614	10/26/99	Ruano et al.	435	6	
<u>AD</u>	6,023,659	02/08/00	Seilhamer et al.	702	19	
<u>AE</u>	6,057,101	05/02/00	Nandabalan et al.	435	6	
<u>AF</u>	6,057,111	05/02/00	Deiss et al.	435	6	
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
<u>AG</u>						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
<u>AH</u>						
EXAMINER <u>[Signature]</u>	DATE CONSIDERED <u>3/6/06</u>					


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 (Modified)		Attorney Docket No.: 195531-001810US		Application No.: 09/808,442		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Hugh Young Rienhoff, Jr., et al.				
		Filing Date: March 13, 2001		Group:		
Reference Designation		U.S. PATENT DOCUMENTS				Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
___ AA						
___ AB						
___ AC						
___ AD						
___ AE						
___ AF						
___ AG						
___ AH						
___ AI						
___ AJ						
___ AK						
___ AL						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
___ AM						
___ AN						
___ AO						
___ AP						
___ AQ						
___ AR						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
AS	Gulcher and Stefansson, <i>Population Genomics: Laying the Groundwork for Genetic Disease Modeling and Targeting</i> , 1998, 36(8):523-527					
___ AT						
___ AU						
___ AV						
___ AW						
EXAMINER <i>M. J. [Signature]</i> DATE CONSIDERED <i>3/6/06</i>						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609/ Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box






PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/808,442
				Filing Date	March 13, 2001
				First Named Inventor	Rienhoff, Hugh Young, Jr. et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	195531-001810US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<i>[Signature]</i>	AA	4,582,788		Henry A. Erlich	4/15/86	
<i>[Signature]</i>	AB	5,075,217		James L. Weber	12/24/91	
<i>[Signature]</i>	AC	5,840,746		Yves Ducharme et al.	11/24/98	
<i>[Signature]</i>	AD	5,935,781		Poirier	08/1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>6</sup> (if known)				
	AE		WO 97/40462	PCT		10/30/97		
	AF		WO 98/38846	PCT		9/11/98		
	AG		WO 98/07426	PCT		2/26/98		

Examiner Signature	<i>[Signature]</i>	Date Considered	3/6/06
-----------------------	--------------------	--------------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9040187 v1

RECEIVED  
APR 22 2002  
TECHNOLOGY CENTER 2800

Please type a plus sign (+) inside this box →



APR 19 2002

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

## Complete If Known

Application Number	09/808,442
Filing Date	March 13, 2001
First Named Inventor	Rienhoff, Hugh Young, Jr. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	195531-001810US

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
nk	AH	Cheung, Kei-Hoi; Nadkarni, Prakash; Silverstein, Scot; Kidd, Judith R.; Pakstis, Andrew J.; Miller, Perry; and Kidd, Kenneth K.; <i>PhenoDB: An Integrated Client/Server Database for Linkage and Population Genetics</i> , <i>Computers and Biomedical Research</i> , August, 1996, Vol. 29, No. 4, pp. 327-337.	
nk	AI	Galfalvy, Hanga C. and Harner, James E., <i>A Statistical Environment for Multivariate Analyses</i> , <i>Proceedings of the 27th Symposium on the Interface Computing Science and Statistics</i> , June 21-24, 1995, Vol. 27, pp. 259-263.	
nk	AJ	Gould, K. Lance, <i>Invasive Procedures In Acute Myocardial Infarction: are they beneficial?</i> , <i>JAMA</i> , The Journal of the American Medical Association, September 21, 1994, Vol. 272, N. 11, p. 891(3).	
nk	AK	Hammond, Janet M. J.; Potgieter, Peter D.; Saunders, G. Lance and Forder, Ardenne A.; <i>Double-bind study of selective decontamination of the digestive tract in intensive care</i> , <i>Lancet</i> , July 4, 1992, Vol. 340, No. 8810, p. 5(5).	
nk	AL	Munakata, Toshinori, <i>Knowledge-based systems for genetics</i> , <i>International Journal of Man-Machine Studies</i> , May 15, 1985, Vol. 23, No. 4, pp. 551-561.	
nk	AM	Ritter, O.; Kocab, P.; Senger, M.; Wolf, D.; and Suhai, S.; <i>Prototype Implementation of the Integrated Genomic Database</i> , <i>Computers and Biomedical Research</i> , April, 1994, Vol. 27, pp. 97-115.	
nk	AN	Schulz, Kenneth F.; Chalmers, Iain; Grimes, David A. and Altman, Douglas G.; <i>Assessing the Quality of Randomization from Reports of Controlled Trials Published in Obstetrics and Gynecology Journals</i> , <i>JAMA</i> , The Journal of the American Medical Association, July 13, 1994, V. 272, N. 2, p. 125(4).	
nk	AO	Srivastava et al., "Pharmacogenomics of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and the Cystic Fibrosis Drug CPX Using Genome Microarray Analysis", <i>Molecular Medicine</i> , Vol. 5, pp. 753-767 (1999).	
nk	AP	Ferrari, "Pharmacogenomics: a new approach to individual therapy of hypertension?", <i>Rapid Science Ltd.</i> , pp. 217-222 (1998).	
nk	AQ	Garry et al., "Estrogen Replacement Therapy. Serum Lipids, and Polymorphism of the Apolipoprotein E Gene", <i>Clinical Chemistry</i> , Vol. 45, no 8, pp. 1214-1223 (1999).	
nk	AR	Kroemer et al., "Molecular Bases and Clinical Consequences of Genetic Cytochrome P450 2D6 Polymorphism", <i>Life Sciences</i> , Vol. 56, no. 26, pp. 2285-2298 (1995).	

Examiner Signature

*Mark A. Gattuso*

Date Considered

3/6/06

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
WC 9040187 v1

Please type a plus sign (+) inside this box → ☐

APR 19 2002

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **3** of **3**

## **Complete if Known**

Application Number	09/808,442
Filing Date	March 13, 2001
First Named Inventor	Rienhoff, Hugh Young, Jr. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	195531-001810US

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ME	AS	Syvanne et al., "A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery", <i>Controlled Clinical Trials</i> , Vol. 18, pp. 93-119 (1997).	
ME	AT	Lichter et al., "What's in a gene: using genetic information for the design of clinical trials", <i>Current Opinion in Biotechnology</i> , Vol. 6, pp. 715-717 (1995).	
ME	AU	Sanders, "Mining the Swedish Clinical Archives to Develop Pharmacogenomic Tests", <i>Molecular Diagnosis</i> , Vol. 4, No. 4, pp. 319-325 (December 1999).	
ME	AV	Nebert, "Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?", <i>Clin Genet</i> , Vol. 56, pp. 247-258 (October 1999).	
ME	AW	Stone et al., "PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial", <i>The Journal of Antimicrobial chemotherapy</i> , Vol. 40, pp. 251-256 (1997).	

RECEIVED

APR 22 2002

TECHNOLOGY CENTER 2800

Examiner Signature

*Max A. [Signature]*

Date Considered

3/6/06

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
WC 9040187 v1